Bacteria engineered to treat diseases associated with hyperammonemia
AssigneeSynlogic, Inc.
InventorsDean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller
Life of this patent
Estimating the term…
Abstract
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
Claims18
A genetically engineered bacterium comprising an arginine regulon,
- wherein the bacterium comprises a gene encoding an arginine feedback resistant N-acetylglutamate synthetase (ArgAfbr), wherein the ArgAfbr has reduced arginine feedback inhibition as compared to a wild-type N-acetylglutamate synthetase from the same bacterial subtype under the same conditions and wherein expression of the gene encoding ArgAfbr is controlled by a promoter that is induced by low-oxygen or anaerobic conditions;
- and
- wherein the bacterium has been genetically engineered to lack a functional ArgR.
A pharmaceutically acceptable composition comprising a genetically engineered bacterium comprising an arginine regulon, wherein the bacterium comprises a gene encoding an arginine feedback resistant N-acetylglutamate synthetase (ArgAfbr), wherein the ArgAfbr has reduced arginine feedback inhibition as compared to a wild-type N-acetylglutamate synthetase from the same bacterial subtype under the same conditions, wherein expression of the gene encoding ArgAfbr is controlled by a promoter that is induced by low-oxygen or anaerobic conditions;
- and wherein the bacterium has been genetically engineered to lack a functional ArgR;
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.